Buy these ‘income darlings’ to boost your portfolio, says Jefferies

Jefferies is steering investors toward dividend-rich, fundamentally strong stocks as geopolitical तनाव and macro uncertainty keep markets volatile. The screen emphasized companies with average dividend yields of 4.3%, payout ratios below 90%, and no dividend cuts in five years, including Target ($140 PT, ~8% upside), CVS Health ($98 PT, ~28% upside), and Zions Bancorp ($70 PT, ~11% upside). The call is defensive rather than a fresh catalyst, but it reinforces a preference for income and ballast amid sharp market swings.

Analysis

This is less a stock-picking note than a regime signal: in a volatility shock, the market is paying up for self-funding balance sheets and ignoring cyclicality until the macro clears. That favors high free-cash-flow “bond proxies” with visible capital return capacity, but it also means the crowd will likely overcrowd the same defensive cohort, compressing upside once headline risk fades. The real edge is in names where the dividend is not just sustainable but a precondition for multiple re-rating because it forces capital discipline and narrows the left tail.

TGT is the cleaner quality/valuation setup, but the second-order catalyst is margin normalization rather than just yield: if inventory discipline holds and discretionary demand stabilizes, earnings leverage can compound faster than the market expects, especially after a violent year-to-date rerating. CVS is a more interesting asymmetric reset trade because the thesis is not yield alone; it is optionality on capital returns if management proves the earnings trough is behind them. That creates a path for both higher payout credibility and buyback reinstatement, which would mechanically shrink the float and support the multiple.

The contrarian risk is that investors are mistaking “defensive” for “insensitive.” If geopolitical stress eases and the Fed narrative turns more growth-friendly, the money rotates out of income names quickly, especially those with modest yields relative to Treasuries. For TGT, any disappointment in traffic or margin recapture would expose how much of the move is sentiment-driven. For CVS, the key failure mode is execution slippage in healthcare margins; the stock will not trade like a dividend stalwart if earnings visibility weakens again.

Key Decisions for Investors

• Long TGT on pullbacks over the next 2-4 weeks; favor a position sized for modest upside capture rather than a breakout chase. Base case is low-double-digit total return as dividend support plus earnings normalization tightens the valuation gap; stop if consumer commentary rolls over or margin recapture stalls.
• Initiate a smaller, higher-conviction long in CVS with a 3-6 month horizon. Risk/reward is more asymmetric than TGT because a credible path to buybacks can re-rate the stock; use if the market is still pricing execution skepticism, and cut if healthcare margins fail to improve sequentially.
• Pair long CVS / short a lower-quality defensive healthcare or retail basket to isolate capital-return optionality from broad market beta. The trade works if investors continue to favor balance-sheet durability but start rewarding visible catalyst paths rather than just yield.
• Avoid chasing the whole dividend screen as a basket. In a risk-off reversal, the crowded income trade can underperform faster than the market; prefer names with a second catalyst such as earnings inflection, buyback resumption, or payout growth potential.
• If volatility compresses and the market rallies on geopolitical de-escalation, trim defensive longs into strength and rotate into cyclical laggards. The income trade should be treated as a ballast sleeve, not a secular momentum bet.